FIELD: biotechnology.
SUBSTANCE: invention relates to CARs (chimeric antigen receptors) that specifically bind to CD70. Also the following is disclosed: engineered immune cells containing CAR data, nucleic acids encoding CARs, and methods of producing CARs, engineered immune cells, and nucleic acids.
EFFECT: invention is effective in the treatment of a condition associated with malignant cells expressing CD70.
58 cl, 15 dwg, 13 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
